Kamphuis J

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review.

Lima Constantino J, de Jager JE, Nuninga JO +3

Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.

Massetti S, Smith-Apeldoorn SY, Veraart JKE +6

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Lima Constantino J, Freimann TS, van Dalfsen JH +5

Effects of ketamine on sleep and circadian rhythmicity in major depressive disorder and bipolar disorder: A systematic review.

Boesjes R, Oosterveld C, Kamphuis J +3

A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +1

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double-Blind Randomized Placebo-Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality.

Strous JFM, Roelandt GHJ, van Dalfsen JH +3

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Veraart JK, Smith-Apeldoorn SY, van der Meij A +3

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.

Veraart JKE, Vos CF, Punt NC +6

The Association between Intranasal Esketamine and Treatment-emergent Insomnia in the Treatment of Treatment-resistant Major Depression: A Meta-analysis.

Türkmen C, Boesjes R, Zandbergen AF +4

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

Veraart JKE, Smith-Apeldoorn SY, Kamphuis J +2

Oral Esketamine as Alternative for Maintenance Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Case Series.

Coerts DT, Veraart JKE, Kamphuis J +3

ArticlePsilocybin

Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.

Constantino JL, van Dalfsen JH, Massetti S +2

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Lima Constantino J, Godschalk M, van Dalfsen JH +5

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +5

Europe PMC2024

ArticlePsilocybin

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.

Breeksema JJ, Niemeijer A, Krediet E +5

Europe PMC2024

PreprintKetamine

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension

Smith-Apeldoorn S, Veraart J, Kamphuis J +5

Europe PMC2023

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.

Breeksema JJ, Niemeijer A, Kuin B +5

Europe PMC2023